Peptide inhibitors of ABL kinases
Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an AbI kinase. Further provided are methods of inhibiting an AbI kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an AbI kinase from a tissue are provided.
1. A method of inhibiting an AbI kinase, the method comprising contacting a cell or tissue expressing the AbI kinase with a purified compound selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:18; and thereby inhibiting the activity of said AbI kinase; wherein said cell or tissue is part of a living mammal that has, or is at risk for, leukemia or prostate cancer.
2. The method of claim 1 , wherein the compound consists of SEQ ID NO:1, wherein the tyrosine at residue 10 is phosphorylated.